

Amendments to the Specification

Please replace the paragraph beginning at p. 36 line 3 with the following paragraph:

For treating or preventing inflammatory disorders mediated by LTB₄, or for treating disorders mediated by TXA₂, or for treating disorders mediated by adenosine, the specific dose of racemic-1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine, or an enantiomer thereof, to obtain therapeutic benefit, is determined by the particular circumstances of the individual patient including, the size, weight, age and sex of the patient. Also determinative is the nature and stage of the disease and the route of administration. Generally, a daily dosage of from about 100 to 1500 mg/day ~~mg/kg/day~~ may be utilized. Preferably, a daily dosage of from about 100 to 1000 mg/day ~~mg/kg/day~~ may be utilized. More preferably, a daily dosage of from about 100 to 500 mg/day ~~mg/kg/day~~ may be utilized. Higher or lower doses are also contemplated.